期刊
CYTOKINE
卷 44, 期 1, 页码 141-148出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.cyto.2008.07.004
关键词
Interleukin 1 beta; Interleukin 1 alpha; Diabetes; Obesity; Hyperglycemia
资金
- Harold L Dorris Neurological Institute
- Skaggs Institute of Chemical Biology
The proinflammatory cytokine Interleukin 1 beta (IL-1 beta) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1 beta antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1 beta antibody treated group showed reduced glycated hemoglobin (*P=0.049), reduced serum levels of proinsulin (*P = 0.015), reduced levels of insulin and smaller islet size (*P = 1.65E-13) relative to the control antibody treated group. Neutralization of IL-1 beta also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (*P = 0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes. (C) 2008 Elsevier Ltd. All rights reserved .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据